الصفحة الرئيسية > الأعضاء > ميلود كادر

ميلود كادر

مستشار في اقتصاد الصحة وتطوير النظم الصحية في البلدان النامية.

> mkaddar@hotmail.com

مستشار في اقتصاد الصحة. عمل لما يزيد عن خمسة وعشرين عاما في مجال الصحة والسكان، والتنمية، انضم الى منظمة الصحة العالمية عام 2002 وقاد فريق العمل المعني بتطوير النظم الصحية في البلدان النامية.
له العديد من المؤلفات العلمية المنشورة في مجلات علمية عالمية.

الإصدارات

Shelabya A., Abdul Rahim H., Abul Naga R., Awawda S., Mataria A., Abu-Zaineh M., Farag M. and Kaddar M Covid-19: Public policy responses and health consequences in the Arab region. Hikama, 1: 141-156.

Hinsch, M., Kaddar, M., & Schmitt, S. (2014) Enhancing medicine price transparency through price information mechanisms. Global Health, 10, 34.

Kaddar, M., Milstien, J., & Schmitt, S. (2014) Impact of BRICS' investment in vaccine development on the global vaccine market. Bulletin of the World Health Organization, 92(6), 436-446.

Saxenian, H., Hecht, R., Kaddar, M., Schmitt, S., Ryckman, T., & Cornejo, S. (2014) Overcoming challenges to sustainable immunization financing: early experiences from GAVI graduating countries. Health Policy and Planning, czu003.

Kaddar M., Schmitt S., Makinen M., & Milstien J. (2013) Global support for new vaccine implementation in middle-income countries. Vaccine, 31, B81-B96.

Makinen, M., Kaddar, M., Molldrem, V., & Wilson, L. (2012) New vaccine adoption in lower-middle-income countries. Health Policy and Planning, 27(suppl 2), ii39-ii49.

Hecht, R., Kaddar, M., & Schmitt, S. (2011) Transparent pricing of vaccines would help poor as well as rich countries. BMJ, 343:d7414. 

Levin, A., & Kaddar, M. (2011) Role of the private sector in the provision of immunization services in low-and middle-income countries. Health Policy and Planning, 26(suppl 1), i4-i12.

Zuber, P. L., El-Ziq, I., Kaddar, M., Ottosen, A. E., Rosenbaum, K., Shirey, M., et al. (2011) Sustaining GAVI-supported vaccine introductions in resource-poor countries. Vaccine, 29(17), 3149-3154.

Chougrani, S., & Kaddar, M. (2010) Expérience de la contractualisation dans le secteur de la santé en Algérie. Journal de Gestion et d'Economie Médicales, 28(5), 179-193.

Milstien, J. B., & Kaddar, M. (2010) The role of emerging manufacturers in access to innovative vaccines of public health importance. Vaccine, 28(9), 2115-2121.

El-Idrissi, D. Z. E., Miloud, K., & Belgacem, S. (2008) Constraints and obstacles to social health protection in the Maghreb: the cases of Algeria and Morocco. Bulletin of the World Health Organization, 86(11), 902-904.

Kaddar M. (2019) Ongoing transition in Maghreb Health Systems: Sustainability of tentative support from external partners (donors, EU and UN agencies). European Journal of Public Health,Vol. 29, Supplement 4.

Kaddar M, Saxenian H and al.(2019) Vaccine procurement in the Middle East and North Africa region: Challenges and ways of improving program efficiency and fiscal space. Vaccine. Volume 37, Issue 27, Pages 3520-3528.

Kaddar M.(2019) Market access for innovative medicines in Algeria: The case of oncology drugs. Algerian Journal of Health Sciences. Vol. 01.

Saxenian H, Sadr-Azodi N, Kaddar M, et al (2019) Immunization financing and programme performance in the Middle East and North Africa, 2010 to 2017. BMJ Global Health.

Hecht R., Kaddar M, and al (2018) Morocco investment case for hepatitis C: using analysis to drive the translation of political commitment to action. Journal of Global Health Reports.

Sloane P. and Kaddar M. (2018) Health Trends in the Middle East and North Africa A Regional Overview of Health Financing and the Private Health Sector. SHOPS Plus and HFG.

Kaddar M. et al. (2018) Immunization Financing in MENA Middle-Income Countries. UNICEF MENA.